Effect of esketamine on emergence agitation after photodynamic therapy for port-wine stains in children: a randomized controlled trial

To evaluate the efficacy and safety of different doses of esketamine for preventing emergence agitation (EA) during recovery after photodynamic therapy in children with port-wine stains. In this double-blind, randomized controlled trial, 459 children aged 1–12 years undergoing elective photodynamic therapy for port-wine stains were randomly assigned to receive subanesthetic-dose esketamine (0.25 mg/kg), conventional-dose esketamine (0.5 mg/kg), or placebo (0.9% normal saline); 454 were analyzed. The primary outcome was the incidence of EA during the post-anesthesia care unit (PACU) stay, defined as a Cornell Assessment of Pediatric Delirium (CAPD) score ≥ 10 at any assessment. Secondary outcomes included EA incidence at 15, 30, 45, and 60 min after PACU admission, FLACC pain score, time to maximum CAPD score, extubation time, and emergence adverse events. Exploratory post hoc analyses assessed effects across scheduled assessments and subgroups. The incidence of EA at any PACU assessment did not differ significantly among the three groups ( P = 0.682). Across scheduled PACU assessments, post hoc analysis showed lower EA odds with 0.5 mg/kg versus placebo (OR = 0.58, 95% CI 0.39–0.85; Holm-adjusted P = 0.010). At 30 min after PACU admission, EA incidence was 13.2% in the 0.5 mg/kg group, 19.5% in the 0.25 mg/kg group, and 26.8% in the placebo group (Holm-adjusted P = 0.046). Bayesian analysis showed a 99.9% posterior probability of benefit for the 0.5 mg/kg dose at 30 min. Time to peak CAPD score and extubation time were prolonged in the 0.5 mg/kg group (both P < 0.01), without serious adverse events. Exploratory subgroup analysis suggested greater benefit among children aged < 72 months. Although 0.5 mg/kg esketamine did not reduce the proportion of children who experienced EA at least once during the PACU stay, exploratory post hoc analyses showed a lower incidence at 30 min and lower odds across scheduled assessments. This benefit was accompanied by a modest prolongation of recovery. Chinese Clinical Trial Registry, ChiCTR2400084394 , registered on 15 May 2024; prospectively registered.

Authors

Institutions

Publication Details

Journal
BMC Pediatrics
Published
2026-11-16
DOI
https://doi.org/10.1186/s12887-026-07887-z
Primary Topic
Anesthesia and Sedative Agents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of esketamine on emergence agitation after photodynamic therapy for port-wine stains in children: a randomized controlled trial

Jinya Shi, jingjie Li, Xun Zhou, Wenxin Zhang et al.
4 links
BMC Pediatrics
Anesthesia and Sedative Agents
article

Effect of esketamine on emergence agitation after photodynamic therapy for port-wine stains in children: a randomized controlled trial

Jinya Shi, jingjie Li, Xun Zhou, Wenxin Zhang, Jinxin Liu
article en

Abstract

To evaluate the efficacy and safety of different doses of esketamine for preventing emergence agitation (EA) during recovery after photodynamic therapy in children with port-wine stains. In this double-blind, randomized controlled trial, 459 children aged 1–12 years undergoing elective photodynamic therapy for port-wine stains were randomly assigned to receive subanesthetic-dose esketamine (0.25 mg/kg), conventional-dose esketamine (0.5 mg/kg), or placebo (0.9% normal saline); 454 were analyzed. The primary outcome was the incidence of EA during the post-anesthesia care unit (PACU) stay, defined as a Cornell Assessment of Pediatric Delirium (CAPD) score ≥ 10 at any assessment. Secondary outcomes included EA incidence at 15, 30, 45, and 60 min after PACU admission, FLACC pain score, time to maximum CAPD score, extubation time, and emergence adverse events. Exploratory post hoc analyses assessed effects across scheduled assessments and subgroups. The incidence of EA at any PACU assessment did not differ significantly among the three groups ( P = 0.682). Across scheduled PACU assessments, post hoc analysis showed lower EA odds with 0.5 mg/kg versus placebo (OR = 0.58, 95% CI 0.39–0.85; Holm-adjusted P = 0.010). At 30 min after PACU admission, EA incidence was 13.2% in the 0.5 mg/kg group, 19.5% in the 0.25 mg/kg group, and 26.8% in the placebo group (Holm-adjusted P = 0.046). Bayesian analysis showed a 99.9% posterior probability of benefit for the 0.5 mg/kg dose at 30 min. Time to peak CAPD score and extubation time were prolonged in the 0.5 mg/kg group (both P < 0.01), without serious adverse events. Exploratory subgroup analysis suggested greater benefit among children aged < 72 months. Although 0.5 mg/kg esketamine did not reduce the proportion of children who experienced EA at least once during the PACU stay, exploratory post hoc analyses showed a lower incidence at 30 min and lower odds across scheduled assessments. This benefit was accompanied by a modest prolongation of recovery. Chinese Clinical Trial Registry, ChiCTR2400084394 , registered on 15 May 2024; prospectively registered.

BMC Pediatrics
Shanghai Jiao Tong University (CN), Shanghai Ninth People's Hospital (CN)
Good health and well-being
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon